phosphorylcholine has been researched along with bms 387032 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Y; Liu, H; Meng, H; Qian, W; Yang, C; Yang, X; You, L | 1 |
1 other study(ies) available for phosphorylcholine and bms 387032
| Article | Year |
|---|---|
SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Oxazoles; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |